Status:
UNKNOWN
DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening
Lead Sponsor:
Peking Union Medical College Hospital
Collaborating Sponsors:
Zhejiang Provincial People's Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Cervical Cancer
Cervical Intraepithelial Neoplasia
Eligibility:
FEMALE
18+ years
Brief Summary
Based on the previous study of NCT03961191 and NCT03960879, we performed this trial to further confirm the accuracy of host DNA PAX1 and JAM3 methylation for cervical cancer screening. This study woul...
Eligibility Criteria
Inclusion
- With uterine cervix intact
- Aged 18 years or older
- With accessible histological results of cervix
- Signed an approved informed consents
- With accessible cervical cytology before harvesting cervical histology
Exclusion
- Not meeting all of the inclusion criteria
Key Trial Info
Start Date :
March 12 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 12 2022
Estimated Enrollment :
459 Patients enrolled
Trial Details
Trial ID
NCT05290428
Start Date
March 12 2022
End Date
December 12 2022
Last Update
March 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730